NCT06545617View on ClinicalTrials.gov

A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

170

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

March 10, 2026

Study Completion Date

January 31, 2028

Conditions

Platinum-resistant Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer

Interventions

DRUG

BAT8006 for Injection

Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~60 minutes.